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      ‘’All models are wrong, but some are useful’’ 
           -George Box, 1978 (Statistician) 
 I therefore opine that a good model allows you to manipulate, play and make mistakes at low 
cost. However, models maybe quite different from the real thing. 
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ABSTRACT 
5-Hydroxytryptamine (5-HT) also known as serotonin is a biomarker in gastrointestinal 
disorder and several other pathological diseases where 5-HT and its metabolite 5-
hydroxyindole-acetic acid (5-HIAA) are implicated. A sensitive and precise method has been 
developed and validated for the determination of serotonin and 5-hydroxyindole-acetic acid in 
human plasma. The method involves a simple protein precipitation step requiring no further 
downstream sample preparation. The method was developed using a Zorbax Eclipse-C8 RP 
(150mm × 4.6mm, 5µm) column (Agilent Technologies, Palo Alto, CA, USA). The column 
temperature was kept at 20°C and the solvent in gradient mode consisted of water with 0.1% 
formic acid (v/v) (B), acetonitrile with 0.1% formic acid (v/v) (C) and ethanol (D) and a UV 
detector at 254nm and the flow rate was maintained at 0.2mL/min. Linearity of the method 
was studied over the range of 0.5-50µg/mL. The correlation coefficient was r
2 
= 0.9823 for 
serotonin and r
2 
= 0.9892 for 5-hydroxyindole-acetic acid which indicates strong correlation 
between the studied concentration of the analytes and the signal. The precision of the method 
for 5-HT and 5-HIAA were achieved based on repeatability with RSD of 3.07-7.73% and 
3.93-9.99% respectively. The percentage recoveries were 83-119% and 84-116% for 5-HT 
and 5-HIAA respectively, which shows good accuracy of the developed method. The limit of 
detection and limit of quantification were 0.5µg/mL and 1µg/mL respectively suggesting 
good sensitivity of the method. The developed method was applied in the analysis of human 
plasma samples from a project related to the determination of serotonin and its metabolite in 
plasma from pathological patients subjected to a diet rich in vegetables.
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1. INTRODUCTION 
1.1 Biology of serotonin 
Neurotransmitters are chemicals that allow signal transmission, and thus communication 
among the nerve cells (neurons). One of the neurotransmitters used by neurons throughout the 
brain is 5-hydroxytryptamine also known as serotonin (5-HT). Serotonin is produced in and 
released from neurons that originate within discrete regions in the brain. Serotonin was 
originally discovered by Italian Vittorio Erspamer in Rome in 1935 [1] and American 
scientists, Maurice M. Rapport, Arda Green, and Irvine Page of the Cleveland Clinic isolated  
and named in 1948 [2]. The name ''serotonin'' is often referred to as a misnomer and reflects 
the circumstances of the compound's discovery [3]. It was initially identified as a 
vasoconstrictor substance in blood serum – hence ''serotonin'', a serum agent affecting 
vascular tone. This agent was later chemically identified as 5-hydroxytryptamine [2] and, as 
the broad range of physiological roles were elucidated, 5-HT became the most widely used 
and preferred name in the pharmacological field. Serotonin is a central and a peripheral 
neurotransmitter. It is biochemically synthesized from the amino acid tryptophan and it plays 
a great role in regulating various physiological functions such as sleep, hemostasis, and 
behavior regulation; in pathological conditions such as carcinoid syndrome, hypertension, 
thrombosis, and in cardiovascular diseases as well as psychiatric and neurological disorders 
such as schizophrenia, Huntington’s disease, including many others [4, 5]. Serotonin is 
widespread in nature and can be found in foods, nuts, and animals.  
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It is synthesized in the serotonergic neurons in the central nervous system and in the 
enterochromaffin cells of the gut constitutes 80% of total production and storage and it is 
subsequently released when triggered by different stimuli [6] such as chemical and electrical 
synapses between taste cells and synapses and from taste cells to sensory afferent fibers.  
Serotonin is generally interconnected to norepinephrine and dopamine (Fig.1). The three 
compounds are monoamine neurotransmitters. While serotonin is involved in cognitive 
impulses, relaxation as shown in the blue ring (Fig. 1), norepinephrine is involved in 
socialization, concentration etc, whereas dopamine is involved in behaviour, cognitive and 
voluntary movements. The three compounds are necessary for mind and emotional stability. 
 
Figure 1. Interconnection between norepinephrine, dopamine and serotonin (monoamine 
neurotrasmitters). 
(Source: http://www.horses-helping-troubled-teens.com/teen-depression.html) 
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Early detection of carcinoid tumour in the small intestine is diagnosed by measuring blood 
serotonin and 5-hydroxyindole-acetic acid (5-HIAA) secreted by the enterochromaffin cells 
[7]. Following the release of 5-HT, it is rapidly sequestered by platelets or otherwise 
metabolised by the liver or kidney to 5-HIAA by the catalytic action of the mitochondrial 
flavoprotein monoamine oxygenase (EC 1.4.3.4) and aldehyde dehydrogenase (EC 1.2.1.3). 
The 5-HIAA is a major metabolite of serotonin and it is often eliminated in urine; this will be 
highlighted in the course of the present research thesis. Serotonin is associated with coronary 
artery disease (CAD), [8]. Age has a defining trend in risk factor on most endogenous 
biological molecules such as cholesterol and homocysteine, these risk factors are often in 
increased levels in advancing age [9, 10], but serotonin seems to be inversely related to age, 
having higher levels in younger age groups in which it has a significant relationship with 
acute cardiac invents  [8]. Serotonin is often tightly bound to protein and thus very small free 
serotonin concentrations can be found in the plasma [11, 12]. 
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1.2 Neurophysiology of serotonin 
Serotonin is a monoamine neurotransmitter that is primarily found in the gastrointestinal (GI) 
tract and central nervous system (CNS). The raphe nuclei (Fig. 2) is a cluster of nuclei found 
in the brain, they are distributed near the midline of the brainstem; hence, it functions to 
release serotonin to the rest of the brain. Furthermore, most serotonin inhibitors, like the 
selective serotonin reuptake inhibitors (SSRI) and antidepressants are generally believed to 
act on the raphe nuclei as their target site. However, there are other physiological functions of 
the raphe nuclei, but such detail is beyond the scope of the present thesis.  
 
Figure 2. The raphe nuclei (where serotonin is active) represents the major nuclei with both ascending 
and descending serotonergic fibers projecting to the forebrain and the descending fibers that extend to 
the medulla and spinal cord. 
(Source: http://www.bio.davidson.edu/courses/genomics/2003/mccord/5-htt.html) 
 
As previously highlighted, about 80% or more of the human body's total serotonin is located 
in the enterochromaffin cells in the gut, where it is used to regulate intestinal movements. 
While the rest of the remnants are synthesized in serotonergic neurons in the CNS where it 
exerts pool of physiological roles, including but not limited to the regulation of mood, 
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appetite, sleep, muscle contraction, and some cognitive functions as well as memory and 
learning; and in blood platelets where it helps to control hemostasis and blood clotting.  
The connection between serotonin receptors and the serotonin neuron (Fig. 3) defines its 
storage site in nerve terminal. Serotonin is stored in small vesicles within the nerve terminal 
of a neuron, the pink colored image in Fig. 3. Electrical impulses arising in the raphe nucleus 
traveling down the axon toward the terminal causes the release of serotonin from small 
vesicles into the synaptic space. Once in the synaptic space, the serotonin binds to special 
proteins, called serotonin receptors, on the membrane of a neighboring neuron. When 
serotonin binds to serotonin receptors 
 
Figure 3. Connection between serotonin receptors and the serotonin neuron. 
(Source:http://psychminded.wordpress.com/2011/10/10/and-i-guess-thats-why-they-call-it-the-blues/) 
 
it causes a change in the electrical properties of the receiving neuron that generally results in a 
decrease in its activity rate. 
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The serotonin present in the synaptic space for a limited time (Fig. 4) is immediately removed 
if it is not bound to a receptor through special proteins called transporters (in green). The 
serotonin transporters are proteins located on the serotonin neuron terminals and they function 
to transport serotonin from the synaptic space back into the neuron where it can be 
metabolized by enzymes. 
 
Figure 4. Connection between serotonin transporter and serotonin neuron. 
(Source: http://www.drugabuse.gov/publications/teaching-packets/neurobiology-ecstasy/section-ii/3-
serotonin-transporters) 
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1.3 Project scope 
Development and validation of a novel method for the determination of serotonin and 5-
hydroxyindole-acetic acid (5-HIAA) in human plasma using liquid chromatography tandem 
mass spectrometry (LC-MS/MS). 
1.3.1 Project significance 
The National Institute of Nutrition and Seafood Research (NIFES) has been involved in 
different human trials where the potential modulation of serotonin through diets and its 
determination in plasma has been proposed as key components to understand the functional 
role of serotonin in mental and physical health. 
Therefore, NIFES is in urgent need of a reliable method for the analysis of serotonin (5-HT) 
and its 5-hydroxyindole-acetic acid metabolite (5-HIAA) in plasma samples. Unfortunately, 
there is a scarcity of published methods for the determination of 5-HT and 5-HIAA in plasma 
using LC-MS/MS. The main focus of the related literature has been on the analysis of 5-HT 
and 5-HIAA in urine. Whereas serotonin is more evident to emotional related routine 
measurements; 5-HIAA is more often measured in the assessment of carcinoid tumours. 
Consequently, it is important to develop a novel and robust method for the determination of 5-
HT and 5-HIAA that can assist NIFES in the analysis of a high volume of plasma samples 
from various nutritional research projects. The new method will be optimised and validated 
and could become part of NIFES battery of nationally accredited analytical methods. 
. 
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1.3.2 Project brief at the onset 
Serotonin is synthesized from the amino acid tryptophan. Tryptophan undergoes a 
hydroxylation reaction to form 5-hydroxy tryptophan (this reaction is catalysed by the enzyme 
tryptophan hydroxylase). 5-hydroxy tryptophan undergoes a decarboxylation reaction 
(catalysed by amino acid decarboxylase) to form serotonin in one of the fate of tryptophan’s 
metabolic pathways. Serotonin subsequently undergoes oxidative deamination followed by 
concomitant oxidation to form 5-hydroxyindole-acetic acid (5-HIAA), which is the 
predominant metabolite in urine. Hence, this metabolite is mainly analysed and studied in 
urine. Therefore, the need for a robust and rapid method using liquid chromatography coupled 
to tandem mass spectrometry in the determination of the parent compound, 5-
hydroxytryptamine and its acid metabolite in human plasma. 
 
1.3.3 Objectives of the study 
 To develop a novel and rapid method for extracting serotonin and 5-hydroxyindole-
acetic acid from human plasma and further quantification by using liquid 
chromatography tandem mass spectrometry (LC-MS/MS). 
 To optimise and validate the developed method. 
 To apply the novel method in the analysis of plasma samples from nutritional 
intervention studies. 
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1.4 Biosynthesis of serotonin 
Serotonin is derived from the amino acid tryptophan. The metabolic pathway through which 
tryptophan is converted to serotonin is outlined in Fig. 5. The first step involves hydroxylation 
of tryptophan to form 5-hydroxytryptophan, 5-HTP. The reaction requires oxygen and it is 
catalysed by a hydroxylase, which is dependent upon the presence of the reduced form of 
coenzyme, niacin adenine dinucleotide phosphate (NADP) also known as triphospyridine 
nucleotide (TPN). In the next step of the biosynthetic pathway, the hydroxylated tryptophan 
(5-HTP) undergoes a decarboxylation reaction to yield 5-hydroxytryptamine (serotonin), this 
decarboxylation reaction is catalysed by a decarboxylase enzyme (aromatic amino acid 
decarboxylase)  also known to be involved in the decarboxylation of other amino acids such 
as tyrosine to form tryramine or of 3-4-dihydrophenylalanine to form dihydrophenylalanine, 
an intermediate precursor of norepinephrine and subsequently epinephrine, another member 
of monoamine neurotransmitter and neuromodulator.  The decarboxylase enzyme requires a 
pyridoxal phospahate (vitamin B6) as a cofactor. This route of production of serotonin from 
tryptophan is thus one of the minor fates of the ubiquitous routes of tryptophan metabolism; 
consequently about one percent of tryptophan takes this pathway.   
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On the contrary, the major route of tryptophan metabolism proceeds through the kynurenine, 
hydroxyanthanilic acid, and quinolinic acid and to nicotinic acid, a very important end 
product of tryptophan metabolism proved by isotopic studies which revealed that the nitrogen 
of the indole ring of pyridine ring of the tryptophan is retained as the nitrogen of the pyridine 
ring of nicotinic acids [13]. 
 
 
Figure 5. The metabolic pathway of tryptophan metabolism to serotonin (5-HT) and subsequently to 5-
hydroxyindole-acetic acid (5-HIAA), [13]. 
 
In many animals, the conversion of tryptophan to nicotinic acid renders the supply of vitamin 
in the diet unnecessary as long as protein containing tryptophan is ingested. In other mammals 
such as rat, rabbit, dog and pig for instance tryptophan can replace completely the vitamin in 
the diet. In humans, about 60 mg of tryptophan produces 1 mg of nicotinic acid, thus this 
implies that the nutritional deficiency of nicotinic acid that often occurs in pellagra must be 
considered a protein and vitamin (tryptophan and nicotinic acid) deficiency respectively [13]. 
11 
 
Biochemically, it may be necessary to observe that carcinoid produces abnormality of 
tryptophan metabolism in which as much as 60 %, other than the normal 1 %, of tryptophan 
may follow the serotonergic pathway. In addition to the production of the excess amines, the 
switch in the metabolism shuts adequate production of nicotinic acid which would lead to 
nitrogen imbalance and subsequently nicotinic acid deficiency. 
Furthermore, the majority of serotonin produced in the tissues is further metabolized via 
oxidative deamination to form 5-hydroxyindole-acetic acid (5-HIAA). The series of this event 
involves the serotonin produced from L-tryptophan subsequently undergoing oxidative 
deamination followed by concomitant oxidation and conjugation in the liver, lungs and 
thrombocytes catalysed by monoamine oxygenase A (MAO-A) and aldehyde dehydrogenase 
(ADH) to form 5-HIAA, which is the predominant metabolite in urine. Hence, this metabolite 
is mainly analysed and studied in urine. Consequently the pertinent of a robust and rapid 
method using the tandem mass spectrometric technique that can simultaneously determine the 
parent compound, serotonin and its metabolite, 5-HIAA in human plasma. A comprehensive 
biosynthetic and degradative pathway of serotonin metabolism is shown in Fig. 6. 
12 
 
 
Figure 6. Biosynthetic and degradative routes in the metabolism of serotonin. 
 
Abbreviations: AADC, aromatic-L-amino acid decarboxylase; Alc DH, alcoholdehydrogenase; Ald 
DH, aldehyde dehydrogenase; HIOMT, hydroxyindole-O-methyl transferase; MAO, monoamine 
oxidase; N-Ac-5HT, N-acetyl-5-hydroxytryptamine; N-Ac-5Mt, N-acetyl-5-methoxytryptamine, 
melatonin; N-Ac-5-HT, N-acetyl-5-hydroxytryptamine; TRP, Tryptophan; TRP Hydr, tryptophan 
hydroxylase; 5-HT, Serotonin, 5-hydroxytryptamin; 5-HTOL, 5-hydroxytryptophol; 5-HTP, 5-
hydroxytryptophan; 5-HIAA, 5-hydroxyindole acetic acid. 
(Adapted from, I. P. Kema et al, 2000: Review of Clinical chemistry of serotonin and metabolites). 
 
1.5 5-HIAA/5-HT ratio in depression 
Depression is often characterised by feelings of guilt and hopelessness, appetite loss, 
insomnia, and suicidal thoughts, consistent sadness, extreme fatigue, etc and serotonin has 
been undoubtedly implicated in this effects. Serotonin is thought to play the critical role in 
depression because of its effects on mood state listed above as well as other cognitive 
processes. Serotonin influences the initiation and then gradual "relaxation" of thoughts. 
Imbalance in serotonin results in ruminating negative self-talk (worry), that is, negative self-
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talk thoughts that keep reoccurring and will not go away, this constitutes a major problem in 
depression. Most of the antidepressants exact their effects by inhibiting serotonin reuptake 
(SRI's). During serotonergic neurotransmission, serotonin is released into the synaptic cleft 
(junction between two neurons), Fig. 4. After exerting its action in the postsynaptic neuron, 
part of the serotonin is transported again into the presynaptic neuron by specific transporters 
(SERT). Once again in the presynaptic neuron, part of this serotonin is incorporated again into 
vesicles (Fig. 3) and part is metabolized by the monoamine oxidase (MAO) and other 
enzymes to form 5-HIAA. In summary, when the serotonergic activity is high, more serotonin 
is released in the synapses, and consequently, metabolized to 5-HIAA. Therefore, the 5-
HIAA/5-HT ratio would be higher. In addition, metabolism of certain body molecules means 
that there is both anabolism (syntheses, in this case from L-tryptophan to 5-HT) and 
catabolism (from 5-HT to 5-HIAA) of that molecule. It is possible to assume on the basis of 
5-HIAA levels that only the impairments in catabolism step, from 5-HT to 5-HIAA 
(impairments in MAO or aldehyde dehydrogenase activity) and not in the syntheses step. 
Serotonin turnover has been reported to be indeed related to stress, and it is known that 
chronic stress may lead to depression. In different animal models it is known that stress 
induce an increase in serotonergic turnover, but often also in dopaminergic and noradrenergic 
turnover [14]. These alterations are transient if the stress is acute (for example a persecution 
by a predator). If the stress becomes chronic (for example, cohabitation with a dominant 
specimen), important and long-lasting changes in the monoaminergic systems could occur.  
Also, chronically stressed animals may present symptoms similar to those observed  
in Major Depressive Disorder, (MDD) patients [14]. The 5-HIAA/5-HT ratio could be useful 
for different purposes. One of them is its use as an estimator of the serotonergic activity (for 
example, a group of acutely stressed rats is expected to have a higher 5-HIAA/5-HT ratio than 
control rats, due to their higher serotonergic turnover).  
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Furthermore, as pointed earlier the biosynthesis of serotonin in humans represents only a 
minor route for tryptophan and in normal conditions this accounts for less than 2% of ingested 
tryptophan, the major part of tryptophan is utilized in protein synthesis and catabolism 
proceeds to give kynurenine and 3-hdroxyanthranilic acid [15,16]. Serotonin synthesis in 
brain is controlled by mechanisms that activate or inhibit tryptophan hydroxylase (the rate 
limiting enzyme in the 5-HT biosynthetic route). Calcium-induced phosphorylation renders 
the enzyme inactive, while an intra-neuronal serotonin pool inhibits it through negative 
feedback mechanism. Irregular variation in tetrahydrobiopterin concentrations could also be 
involved in the regulation of tryptophan hydroxylation roles and actions [17].  
Serotonin and 5-HIAA are mainly excreted in free forms whereas the minor catabolic product 
of serotonin; 5-hydroxytryptophol is predominantly excreted as a conjugate. As a potent 
vasoactive amine, serotonin in circulation is almost completely confined to platelets [12] and 
thus functionally rendered inactive.  
Elevated plasma serotonin are hazardous, many rapid elimination mechanisms have evolved 
to clear excess 5-HT. Platelets possess an active serotonin reuptake system [18], the liver 
catabolises serotonin, pulmonary endothelial cells take up serotonin while some 
macromolecules binds free serotonin. Liver is also involved in the clearance of excess 
serotonin in the plasma with subsequent formation of 5-HIAA. 
1.6 Stability of serotonin 
Serotonin is well known to be an unstable compound, it degrades almost completely if not 
properly and carefully treated. For example 5-HT decomposes at high temperature and at 
acidic pH, but at pH 6 it is stable up to 35°C [19]. Serotonin can be preserved in EDTA 
because the compound chelates metal ion thus prevents decomposition. In a broader sense, the 
instability of serotonin can be circumvented by employing several pre-analytical 
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considerations such as immediate refrigeration after sample collection, avoidance of repeated 
thawing and freezing, acidification (pH>2), and addition of antioxidants such as ascorbic acid, 
perchloric acid, sodium metabisulfite, L-cysteine, EDTA etc. 
It has been reported that the stability of serotonin and 5-HIAA is poor in acidic medium that 
only contain Na2EDTA [19]. Markedly improvement can be noticed with the addition of L-
cysteine and ascorbic acid. It had been observed that the ability of Na2EDTA to complex 
metal ions diminishes at pH below 5 and the strength of ascorbic acid to act as antioxidant 
diminishes at lower pH, since the protonation reduces its ability to become oxidized. 
16 
 
2. THEORETICAL BACKGROUND 
2.1 Analysis of serotonin by chromatography 
There has been an increased interest in serotonin chemistry. This interest could be attributed 
to the increased availability of HPLC methods for research and routine studies. A 
considerable number of articles published in the mid-80s employed this technique with 
different detections in the study of serotonin in biological matrices. Analyses of serotonin and 
its major metabolite, 5-hydroxyindole-acetic acid (5-HIAA) are indispensable for the study of 
their pathophysiological roles. While serotonin is more evident to emotional related routine 
measurements, its metabolite, 5-HIAA is more often measured in the assessment of carcinoid 
tumours. Compared to other biogenic amines such as catecholamines and histamine, serotonin 
can be said to be recently discovered. Studies have elucidated its main function significance in 
recent years.  
The presence of serotonin in tissues is still a subject of investigation [20] and such 
investigation will not have been possible without the development of accurate, reliable, 
precise, and sensitive methods for the analyses of serotonin and its metabolites in biological 
fluids. Several analytical methods have been applied in quantitative and qualitative 
determination of serotonin in various derivatives of blood. An overview (Table 1) of the 
different methods for the analysis of serotonin in human plasma revealed that 33.3% of the 
reported articles used HPLC with fluorometric detection, 40.4% electrochemical detection, 
10.1% employed radioimmunoassay techniques, while only 1.01% used gas chromatography 
and 6.06% used other types of assays such as electrochemical sensors and biosensor based 
techniques. It is evident from (Table 1) that electrochemical detection is the most popular 
method for serotonin analysis in plasma [21, 22]. 
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Table 1. Overview summary of the analysis of plasma serotonin using different analytical techniques 
and their respective detected concentrations of serotonin in (nmol/L). 
Method  Conc. Year Ref no. 
Other 11 1954 70 
Spectrophotoflurometric 79.5 1962 71 
Spectrophotoflurometric 114 1963 72 
Spectrophotoflurometric 73.8 1965 73 
HPLC (fluorometric) 34.1 1968 74 
Spectrophotoflurometric 114 1975 75 
Immunoassay 36 1976 76 
HPLC (fluorometric) 40.3 1979 77 
Radioenzyme 38 1979 78 
Other 100 1979 79 
HPLC (fluorometric) 179 1979 80 
HPLC (fluorometric) 99.6 1981 81 
Radioenzymatic assay 22.6 1981 82 
Immunoassay 9 1982 24 
Radionenzymatic assay 12 1984 25 
HPLC (EC) 44 1984 83 
HPLC (EC) 15.9 1985 84 
HPLC (fluorometric) 160 1985 85 
HPLC (fluorometric) 10.8 1985 86 
HPLC (fluorometric) 13.6 1985 87 
HPLC (EC) 5 1986 88 
HPLC (fluorometric) 3.3 1987 89 
HPLC (EC) 14.6 1987 90 
HPLC (EC) 9.1 1988 91 
HPLC (fluorometric) 4.86 1988 92 
HPLC (EC) 13.9 1988 93 
HPLC (EC) 14 1988 94 
HPLC (EC) 5.28 1988 95 
HPLC (fluorometric) 10.2 1989 96 
HPLC (EC) 30.1 1989 97 
HPLC (EC) 8.51 1989 98 
HPLC (EC) 15 1989 99 
Radioenzymatic assay 2 1990 100 
Radioenzymatic assay 2.5 1990 101 
HPLC (EC) 26.1 1990 102 
Other 66 1990 103 
HPLC (EC) 2.2 1990 104 
HPLC (fluorometric) 4.31 1990 105 
Immunoassay 19 1991 106 
HPLC (EC) 31 1991 107 
 
18 
 
HPLC (EC) 141 1992 108 
HPLC (fluorometric) 28 1992 109 
Radioenzymatic assay 2.8 1992 110 
HPLC (fluorometric) 17 1992 111 
HPLC (EC) 119 1992 21 
Radioenzymatic assay 2.6 1993 112 
HPLC (EC) 6.7 1993 113 
HPLC (fluorometric) 18.5 1993 114 
GC-MS 0.77 1993 115 
HPLC (EC) 94.3 1993 116 
HPLC (EC) 2.8 1993 117 
Radioenzymatic assay 3.4 1994 118 
HPLC (fluorometric) 39.7 1994 119 
HPLC (fluorometric) 61 1995 120 
Radioenzymatic assay 1.05 1995 121 
Radioenzymatic assay 0.6 1995 122 
Other 9.08 1995 123 
Other 14.2 1995 124 
HPLC (EC) 14 1996 125 
HPLC (fluorometric) 15.5 1997 126 
HPLC (fluorometric) 3.5 1998 127 
HPLC (EC) 16.85 1998 128 
HPLC (EC) 14.6 1998 129 
HPLC (EC) 39.6 1998 130 
HPLC (EC) 10.8 1999 131 
Spectrophometry 54.2 1999 132 
HPLC (EC) 161 1999 133 
Radioenzymatic assay 9.6 2000 134 
HPLC (EC) 11 2000 135 
HPLC (fluorometric) 16.9 2000 136 
HPLC (EC) 3.52 2000 137 
HPLC (fluorometric) 32.9 2000 138 
HPLC (EC) 32.3 2003 139 
HPLC (EC) 3.73 2003 140 
HPLC (fluorometric) 25.5 2003 141 
HPLC (fluorometric) 5.7 2004 142 
HPLC (fluorometric) 6 2004 143 
HPLC (EC) 42.6 2004 144 
HPLC (EC) 26 2004 145 
HPLC (EC) 9.8 2004 146 
Immunoassay 2.6 2004 147 
HPLC (fluorometric) 1.8 2005 148 
HPLC (EC) 33 2005 149 
HPLC (EC) 15 2005 150 
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HPLC (fluorometric) 13.1 2006 151 
HPLC (fluorometric) 21.3 2006 152 
HPLC (EC) 33.5 2006 153 
HPLC (EC) 90.8 2006 154 
Immunoassay 50 2006 155 
Immunoassay 10 2007 156 
Other 10.1 2007 157 
HPLC (EC) 90 2007 158 
HPLC (EC) 63.1 2007 159 
HPLC (fluorometric) 10.2 2007 160 
HPLC (fluorometric) 12.7 2007 161 
Immunoassay 40 2008 162 
Immunoassay 0.63 2008 163 
HPLC (EC) 44 2009 164 
Immunoassay 12.3 2010 165 
LC-MS/MS 4.6 2010 53 
 
However, fluorometric methods for serotonin determination are not specific and are preceded 
by poor separations from interfering compounds (poor selectivity), while radio-isotopic 
method are outrageously expensive to be employed in routine analysis. Thin layer 
chromatography [23], radio immunoassay [24, 25], enzyme immunoassay [26], gas 
chromatography mass spectrometry [27-31], HPLC with UV [32], electrochemical detection 
(EC), [33], and mass spectrometry [34] all have been employed in the determination of 
serotonin and consequently other related indoles and biogenic amines in biological fluids. 
Although different kinds of detectors have been applied in conjunction with the HPLC, EC 
detectors are the most popular [35-38]. Notwithstanding the popularity of HPLC with EC 
detectors, liquid chromatography mass spectrometry either  single or tandem have been 
successfully employed in the determination of 5-HT in a wide range of biological fluids or 
tissues [39-48].  
In addition, the use of Liquid chromatography tandem mass spectrometry (LC-MS/MS) for 
determining serotonin in other body fluids are widely reported but to the best of our 
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knowledge there are few reported validated method using the LC-MS/MS technique in 
determination of serotonin in plasma. Liquid chromatography tandem mass spectrometry has 
a wide application in the analyses and quantification of biological fluids; its robust nature 
cannot be over emphasized [49]. LC-MS has evolved into a technique characterized by 
sensitivity, selectivity, and specificity, allowing for the analysis of trace amounts of target 
analytes in complex mixtures such as biological fluids. LC-MS either tandem or single has 
been applied in determination of serotonin in wide variety of biological samples such as gut 
lavage fluid [50], tissues [39], plasma, whole blood [41], serum [49] urine [51, 52], brain and 
cell cultures including many others. Furthermore, it has been reported that the use of LC-
MS/MS in the analysis of serotonin offers merits in relation to specificity and linear range, as 
well as permitting for simultaneous determination of its metabolites [41]. There are a number 
of clinical applications of LC-MS, the technique is more generally applicable than gas 
chromatography mass spectrometry (GC-MS); this is due to the broader range of biological 
molecules that can be analysed and more powerful use of LC separations in clinical 
laboratories. This trend of preferring LC-MS over LC with conventional detectors could be 
traced to the high specificity and its ability to handle complex mixtures.  
Moreover, it is generally supposed that the highly specific nature of LC-MS/MS allows the 
use of short chromatographic run time, minimal sample clean-up and devoid of derivatisation 
which is often the case with GC. However, as the demand continues to grow for the analyses 
of drugs in body fluids, the most common preferred chromatographic technique is gas 
chromatography; it permits efficient separation with sensitive detection of the analytes in 
complex matrices. 
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2.2 Mass spectrometry and chromatography 
Mass spectrometry (MS) is an analytical technique that produces spectra of the masses of the 
atoms or molecules of a sample. The spectra are employed to determine the elemental 
or isotopic identity and composition of a sample, the masses of particles and of molecules, 
and to elucidate the chemical structures of molecules, such as serotonin [53] and wide variety 
of chemical compounds. An MS works by ionizing chemical compounds to generate charged 
molecules or molecule fragments and measuring their mass-to-charge ratios. A diagram of 
tandem mass spectrometry is show in Figure 7.  
 
Figure 7. Schematic of tandem mass spectrometry 
(Source: http://en.wikipedia.org/wiki/Tandem_mass_spectrometry) 
A sample is injected into the mass spectrometer, ionized and accelerated and then analyzed by mass 
spectrometry (MS1). Ions from the MS1 spectra are then selectively fragmented and analyzed by mass 
spectrometry (MS2) to give the spectra for the ion fragments.While the diagram indicates separate 
mass analyzers (MS1 and MS2), some instruments can utilize a single mass analyzer for both rounds 
of MS. 
 
MS are usually classified on the basis of how the mass separation is accomplished, but they 
all can be described as ion optical devices which separate ions according to their mass-to-
charge (m/z) ratios by utilizing electric and/or magnetic force fields.  
The concept of MS is to form ions from a sample, to separate the ions based on their m/z ratio 
(this can be considered to be the same as the mass because the ion has only a single charge in 
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most cases), and to measure the abundance of the ions. In modern MS instrumentation, all of 
the functions (ionization, separation of the ions, rate of data acquisition, detection of the ions, 
and storage of the data) are under computer control. Gaseous molecules are ionized in the ion 
source to form molecular ions in which some will fragment. By various processes, ions of 
differing m/z values pass through the mass analyzer once at a time to reach the detector. When 
the ions strike the detector, they are converted into an electrical signal, which in turn is 
converted into a digital response that can be stored by the computer. Furthermore, powerful 
new technologies of ion-analyses (tandem MS, time-of- flight MS, ion-trap MS) substantially 
increased the capabilities of MS analyzers with respect to specificity and to the extent of data 
read out. These developments suggest a more widespread use of MS techniques superior to 
other analytical methods in routine laboratory medicine. The knowledge of the m/z of the ions 
enables one to determine what is present, while the measured ion intensities answer the 
question of how much is present. Only ions are detected in mass spectrometer and any 
nonionic particles that have no charge are removed from the mass spectrometer by the 
continuous pumping that maintains the vacuum. The effluents from the chromatographic 
column are introduced into the mass spectrometer and it then enters the ionisation chamber 
through the capillary to which a charge is applied. The charge droplets emerge from the tip of 
the capillary and the charge to volume ratio increases as the droplets evaporate. The positive 
charges are repelled and free proton-adducts of the molecules emerge. The adducts are 
selected in an electromagnetic field in the first quadrupole according to their mass to charge 
ratio (m/z). From there they enter the second quadrupole, where they are collided with gas 
molecules, usually nitrogen, and thus fragment to form product ions, also called daughter 
ions. Consequently, the abundant product ion is selected in the third quadrupole according to 
its m/z ratio and allowed to reach the detector.  
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Furthermore, since tandem mass spectrometry is a selective method, several ions may be 
measured even if they are not distinctly chromatographically separated; this is achieved by 
monitoring several molecular transitions intermittently, also called multiple reactions 
monitoring (MRM). The amount of analyte in a sample may not correlate directly with the 
ion-current intensity of its mass spectrometric signal. 
2.2.1 Low pressure chromatography  
Chromatography systems are often defined by their pressure characteristics, acronyms such as 
LPLC and HPLC are used to refer to low-pressure and high performance liquid 
chromatography respectively. Low pressure chromatography operates at a pressure <50psi 
(~3bar), thus they are often used for sample purification and simple protein separations that 
do not require high resolutions. Low pressure chromatography techniques are time 
consuming, their retention times are excessively long (over 30 minutes for 5-HT/5-HIAA), 
they exhibit poor limit of detection and thus may not be suitable for a routine analysis because 
of the poor sample through-put, also such techniques are often encompassed by poor 
sensitivity and thus unreliable [54-56]. Low pressure chromatography systems can only force 
liquid along flow path provided the pressure capabilities of the systems exceeds the resistance 
or back pressure after the pump. However, LPLC has some advantages over HPLC in that the 
tubing and pumps used in low pressure chromatography are easy to clean or replace and thus 
clogging the pump and cross contamination are often not a source of worry. They are 
inherently easier to use and maintain and are less prone to licking etc. 
2.2.2 High performance liquid chromatography 
HPLC is an improved form of column chromatography that is used to separate, purify, 
identify and quantify chemical compounds. Chromatography uses the principle of the 
differences in surface interaction between analytes and eluent molecules to separate 
compounds within one sample. In HPLC system, the analytical instrument composes of two 
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phases. The stationary phase (absorbent) is the solid support situated within the column often 
packed with silica bonded hydrocarbons. The mobile phase (eluent) refers to the solvent 
which is continually added to the column. When injecting a sample into the instrument it will 
migrate through the column according to its affinity to the mobile and stationary phases, this 
means compounds that have less strong affinity to the mobile and stationary phases will elute 
faster than compounds that have stronger affinity to the phases. In HPLC system the 
continuously applied pressure ensures that the analytes and the mobile phase are forced 
through the densely packed column.  A HPLC block diagram is shown in Figure 8. 
 
Figure 8. Set up of a reverse phase HPLC system showing the pump, injection port, column, detector 
and a read out (display) system. 
(Source: http://www.lab-training.com) 
 
The majority of HPLC applications are covered under reversed phase chromatography. 
Stationary phases mostly comprise of non-polar alkyl hydrocarbons such as C-8 or C-18 
chains bound to silica or other inert supports.  Mobile phases maybe polar or weakly polar and 
the elution order of the compounds is polar followed by less polar or weakly polar and non-
polar compounds in the end. 
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2.3 Sample preparation/extraction methods for serotonin in plasma 
There are several clean-up procedures during the analysis of biological fluids. This includes 
the selective clean-up of sample by selective removal of all endo- and exogenous compounds 
in the matrix that could clog the chromatographic column or interfere with the separation of 
the analyte of interest. Several sample preparation techniques have been used for clean-up of 
complex matrices in plasma and other bio-fluids. Such techniques include solid phase 
extraction (SPE) [57-59], protein precipitation [60], liquid-liquid extraction (LLE) as well as 
online solid phase extraction (SPE) [49]. In most bioanalytical methods, the sample 
preparation is usually done by liquid-liquid extraction or solid phase extraction.  
LLE is a method used to separate compounds based on their solubility in two immiscible 
liquids, usually water and organic solvents; thus, it is an extraction of a substance from one 
liquid into another liquid. LLE is highly selective, depending on the choice of the solvent and 
pH, the analytes can be extracted from most of the endogenous compounds and recoveries can 
be improved by successive extractions. On the other hand, SPE is a separation process by 
which compounds that are dissolved or suspended in a liquid mixture are separated from other 
compounds in the mixture according to their physical and chemical properties; with SPE 
technique many of the drawbacks associated with LLE can be avoided, such as incomplete 
phase separation, poor recoveries, and use of expensive fragile glassware as well as use of 
large quantities of organic solvents. SPE is more efficient than the LLE; it is more rapid and 
can be automated. However, both of these methods are laborious and tedious and often 
imprecise. Thus, since the present work also aims at developing simple and reliable sample 
preparation techniques for the analysis of serotonin and its metabolite, 5-hydroxyindole-acetic 
acid, it is therefore, particularly important to consider sample preparations that is less 
laborious, but still efficient. Protein precipitation with miscible organic solvents (such as 
acetonitrile) has been successfully employed in preparation of plasma samples because of its 
26 
 
low cost and minimal method development requirements. This method involves the addition 
of organic solvent, vortex mixing and subsequent centrifugation to separate the resultant 
protein precipitates from the analytes and it provides sufficient clean-up for LC-MS/MS 
analyses. 
2.4 Theory on internal standard 
Internal standard (IS) is a chemical substance with very similar but not necessarily identical 
physicochemical properties to the analyte and it provides several advantages in the analysis of 
biomolecules by liquid chromatography tandem mass spectrometric (LC-MS/MS). It is often 
added in a constant amount to the samples in a chemical analysis to aid in quantification, this 
is also known as spiking. It is very advantageous in that: it improves intra injection 
reproducibility, it corrects the loss of analyte during sample preparation and it markedly 
reduces matrix interferences and ionization effects. An IS can be a structural analogue or 
stable labelled internal standard but the latter is often preferred in bioanalysis.  
During chromatographic quantitative analysis using the IS method, the analyte concentration 
can be determined using the response factor (the ratio of the sensitivities of the analyte and 
the internal standard). The IS needs to provide a signal that is similar to the analyte in most 
ways but markedly distinguishable by the instrument. It is believed that stable labelled 
internal standard yield better assay performance in bioanalytical liquid chromatography mass 
spectrometry assays. Internal standard with similar chemical properties as the analyte may 
cover up assay problems with stability, recovery, and ion suppression. However, stable 
labelled internal standards are not always available and are very expensive; thus structural 
analogues can also be used as IS.  
Using IS in quantitative bioanalysis by liquid chromatography tandem mass spectrometry is 
mainly aimed to compensate for matrix/measurement effects [61].  
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Mass detection unarguably represents unequalled sensitivity and selectivity and it is thus a 
clear candidate for LC-based quantitative assays. Quantitative detection is often complicated 
by effect of matrix interferences, for example in plasma or urine constituents. When an 
analyte is introduced into the ion source it will compete with other compounds introduced into 
the ion source simultaneously. The matrix components decreases the analyte signal, this is 
known as ion suppression, most notably in electrospray ionisation (ESI)-based MS detection 
as used in this thesis. The extent of ion suppression will largely depend on the chemical 
structure of the analyte of interest; which entails that if an analyte and IS are not structurally 
similar, the ratio of analyte and IS detectors responses may vary due to different degrees of 
ion suppression, thereby compromising the quantitation.  
In HPLC analysis a solution of a known analyte ([A]) and internal standard ([IS]) 
concentration is often first run under certain column conditions. The ratio of the detector 
signal of the analyte (SA) and the internal standard (SIS) is calculated to measure the response 
factor (RF) using Eq.1. Subsequently a known concentration of the internal standard and the 
calculated RF are used to determine the concentration of the unknown analyte by solving [A] 
in (Eq.1). 
      
    
   
 
  
   
                                                             Eq. (1) 
 
2.5 Experimental design and optimisation 
Experimental design and optimization are tools that are used to systematically examine 
different types of problems that arise within research, development and production. 
Experimental design such as response surface and factorial design are multivariate approach 
suitable for development of analytical methods. Experimental design is a powerful tool to 
reduce large number of data to manageable size to examine the effects of experimental 
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variables and their interactions and to optimise simultaneously methodological and/or 
instrumental conditions. 
2.5.1 Doehlert design 
Doehlert design is a type of multivariate experimental design where different factors are 
studied at different number of levels. It is often referred to as a uniform shell design in that 
there is a regular distribution of experimental points on the surface of the spherical shells. A 
diagram of Doehlert uniform shell design for two variables is shown in Fig. 9.  
 
Figure 9. Spatial distribution of experimental points in a two-factor Doehlert uniform shell design, 
[62] 
 
The design displays an equally spaced distribution of experimental points circumscribed to a 
sphere of radius 1, in this way the variance of the estimated response is the same at all points 
on the sphere centered at the origin [62]. For a number of K factors, the total number of 
experiments to be measured is given by        ; hence the total number of experiments 
for two variables is 7.  
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The two-factor Doehlert design (Fig. 9), is a hexagon with vertices 2, 3, 4, 5, 6 and 7 and a 
central point 1, The hexagon in question define five levels (-1.00, -0.50, 0.00, +0.50, +1.00) 
for factor 1 (X1) and three levels (-0.866, 0.00, +0.866) for factor 2 (X2). 
Doehlert uniform shell design is an appropriate tool to model the response factor (RF) 
behaviour as a function of the concurrent variation of the concentrations of internal standard 
and analyte [63]. Such model can be a first (Eq. 2) or second (Eq. 3) order  polynomial 
function. 
                                                                       Eq. (2) 
                                     
        
         Eq. (3)  
where    is the intercept 
   and    - the linear term coefficients 
   - the interaction coefficients  of the analyte [A] and [IS]. 
   and   represents the effect of the second order coefficients. 
 
2.6 Matrix effects 
Matrix effect is the combined effect of all components of the sample other than the analyte to 
be quantified. This often affects the selectivity of a bioanalytical techniques and it is 
frequently the case when using liquid chromatography tandem mass spectrometry in 
bioanalysis. In order to minimize matrix interferences in LC-MS/MS a number of approaches 
can be applied. Such approaches can be instrumental modifications or method improvements, 
such as extraction modification, ionisation switching as well as monitoring the elution 
solvents.  
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Matrix effect is not solely unique to LC-MS/MS detectors but has also been observed in other 
detectors such as fluorescence [64] and electron capture techniques.  
Other detectors used in gas chromatography can cause matrix irreproducibility, for instance 
flame dampening caused by lipids and some plasma constituents has been observed in flame 
photometric (FPD) or mass spectrometry (MS) detectors in GC [65]. Thus matrix effects may 
not be solely related to the interferences during ionisation process of LC-MS/MS or sample 
preparation and extraction but should be well-thought-out when developing new analytical 
methods in which reproducibility, robustness, limit of detection and quantification as well as 
other analytical parameters are of paramount importance.  
2.7 Theory on method validation 
Method validation encompasses the procedures of establishing the performance characteristics 
and limitations of a method and the identification of the influences which may change these 
characteristics and to what extent. Specifically, according to the International Standard 
Organisation (ISO/IEC 17025), method validation is the process of proving that an analytical 
method conforms and fulfills the requirements for the intended use. It is aimed at 
demonstrating that the procedure when correctly applied, produces results that are fit for 
purpose [66].   
The analytical parameters that are often considered in method validation include: accuracy, 
precision, repeatability, intermediate precision, specificity, detection limit, quantitation limit, 
linearity and range. 
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2.7.1 Accuracy 
The accuracy of an analytical procedure is defined as the closeness of agreement between an 
accepted conventional true value or an accepted reference value and the experimental value. 
This is often referred to as trueness. 
There are different approaches used to assess accuracy of an analytical method, these 
technique includes but not limited to (i) comparing the result of the analytical measurement 
with a certified reference value, this approach assumes that the uncertainty of the reference 
method is known; (ii) analysing a sample of known concentration and comparing the results 
of the analytical method in question with an established reference method; (iii) when the 
certified control samples are not available, a blank matrix of interest can be spiked with a 
known concentration of the analyte and the percentage of recovery is calculated; (iv) use of 
the standard addition method [67-69].  
Furthermore, following the extraction of the analyte from the matrix and subsequent 
submission to the analytical instrument, its recovery can be determined by comparing the 
calculated (Ccalculated) and nominal (Cnominal) concentrations by using the following expression 
[68]. 
          
           
        
                                        Eq. (4) 
2.7.2 Precision 
The precision of an analytical procedure expresses the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the same analytical conditions.  The International Conference on 
Harmonization (ICH) has defined precision to contain three components: repeatability, 
intermediate precision and reproducibility.  
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Precision of an analytical method can be determined based on standard deviation (SD), 
relative standard deviation (RSD) also known as coefficient of variation (CV), or Variance 
(SD
2
) of the analytical measurement results.  
The equations used for determining the SD and CV parameters are: 
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∑      ̅      
   
                                            Eq. (5) 
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                                                        Eq. (6) 
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                                                    Eq. (7) 
where    ̅ is the mean value, n is the number of measurements.  
2.7.3 Specificity/selectivity 
Specificity/selectivity refers to the ability of an analytical method to differentiate the analytes 
or the internal standard from closely related endogenous matrices. According to 
recommendation of the International Union of Pure and Applied Chemistry (IUPAC), the 
term selectivity is defined as the extent to which an analytical method can determine 
particular analytes under given conditions in mixtures or matrices, simple or complex, without 
interferences from other components. Specificity is the “ultimate” of selectivity [68, 69]. 
Notwithstanding, the term specificity entails that there is no interference or that there is 100% 
selectivity.  
There are several approaches to assessing the selectivity of a method: (i) comparison of 
chromatogram of a blank sample with and without spiking known analytes; (ii) analysis of 
standard or certified reference material; (iii) comparison of the chromatographic response of 
the sample with or without matrice interference [68].  
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Specificity in liquid chromatography is obtained by selecting optimal columns and setting 
chromatographic conditions, such as eluent composition, column temperature and detector 
wavelength. 
2.7.4 Linearity 
The linearity of an analytical method is its ability to obtain a test result which is directly 
proportional to the concentration of analyte in the same sample within a given range. 
Linearity is generally demonstrated by using a series of standards (dissolved in pure solvent 
or spiked in a blank sample) at a minimum of five levels of concentrations, determining the 
intensity of the signals generated by the standards, constructing the signal versus 
concentration curves and performing regression and statistical analysis to judge whether or 
not the linearity over the studied range is fulfilled. Validation of linearity is often regarded as 
a verification of the assumed response function without or with an acceptable deviation. It is 
primarily performed by means of graphical evaluation of the experimental data from the 
assumed response model (residual analysis), also called residual plots. For linear ranges, the 
deviations should be equally distributed between positive and negative values when the 
residual are plotted. Linearity is expressed mathematically as: 
                                                                          Eq. (8) 
where   is the analytical response,   is the amount (or concentration) of analyte,   is the 
sensitivity (or slope of the calibration curve),   is the intercept of the calibration curve (error 
of measurement of the dependent variable -  ).         
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There are statistical established means of determining each of the defined parameters above 
based on least square method of linear regression analysis: 
 
   
  ∑     ∑  ∑  
 ∑       ∑    
                                                            Eq. (9) 
 
     
∑     ∑   ∑  ∑    
 ∑    ∑    
                                                     Eq. (10) 
    
  ∑     ∑  ∑  
√  ∑      ∑       ∑      ∑     
                                     Eq. (11) 
                                     
The correlation coefficient ( ) is often used to explain linearity, and an analytical method is 
most times reported as being linear if    is close to unity. The term is used as a measure of the 
strength of the relation between the dependent and independent variables. In other words it 
measures the relationship between a concentration and the signal. However, low   does not 
necessarily mean that there is no relationship between the variables, just that it is not a linear 
relationship. 
2.7.5 Range 
The range of an analytical method is the interval between the upper and lower values that is 
proven to have a suitable level of precision, accuracy, and as well demonstrate to be linear 
using a particular analytical method. The range must be expressed in the same unit as the test 
results. 
2.7.6 Limit of detection and Limit of quantification 
Limit of detection (LOD) is the lowest concentration that can be measured (detected) but not 
necessarily quantified by a given analytical procedure with statistical significance. It is the 
point at which a measured point is larger than the uncertainty associated with it.  
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In chromatography, the detection limit is the amount injected that produces a peak with a 
height at least two or three times higher than the baseline or noise level. Limit of 
quantification (LOQ) is the smallest amount or the lowest concentration of a substance that 
can possibly be determined by means of a given analytical procedure with established 
accuracy, precision and uncertainty.  
There are several approaches to determine the detection and quantification limits of an 
analytical method [68], such approaches include: 
 Visual assessment: in this approach the detection limit is determined by analysing 
samples of known concentration and establishing the minimum level at which the 
analyte can be conveniently detected. 
 Based on the standard deviation of the blank: this involves the measurement of the 
analytical background performed by analysing an appropriate number of blank 
samples and calculating the standard deviation of the responses.  
 
By using a minimum of six blank analyses results, the limit of detection is expressed as the 
analyte concentration in relation to the sample blank value added to three times the standard 
deviation. 
       ̅                                                 Eq. (12) 
       ̅             )                                  Eq. (13)  
 
where  ̅ is the mean concentration of the analyte in a sample,          is the standard 
deviation of the blank sample. However, there are other procedures to determining the LOQ 
other than using Eq.13, such as using 6 or 7xSDblank with acceptable accuracy and precision. 
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 Determination from the calibration curve at low concentration, whereby a minimum of 
three concentrations near to the estimated quantification limits are analysed and linear 
regression of the points computed to determine the LOD and LOQ. 
         
     
 
                                           Eq. (14) 
        
     
 
                                            Eq. (15) 
where SDres-residual standard deviation 
A graphical illustration of the analytical paramaters is show in Fig. 10. 
 
Figure 10. Graphical illustration of linearity, measuring range, limit of detection, limit of quantitation, 
and sensitivity [68]. 
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3. METHOD DEVELOPMENT 
3.1 Reagents 
Serotonin hydrochloride (cat No. H9523)      purity and internal standard 5-
methoxytryptamine (Cat No. 286583)      purity, 5-hydroxyindole-3-acetic acid,      
purity (CAS No.54-16-0) were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). 
Deuterated internal standard, 5-hydroxyindole-3-acetic-2,2-d2 acid (CAS No. 56209-31-5) 
     purity was purchased from CDN Isotopes Inc. (Pointe-Claire Quebec, Canada). 
HPLC-grade acetonitrile and ethanol were from Merck (Darmstadt, Germany) and formic 
acid (     purity) was from Fluka Chemie (Basel, Switzerland). De-ionised water was 
purified in a Milli-Q system (Millipore, Milford, MA, USA). 
3.2 Plasma samples 
Blank plasma used for developing and validating the method was from an anonymous donor. 
A set of 10 plasma samples from an anonymous clinical biobank involving pathological 
patients subjected to a diet rich in vegetables (Cancer and Diet Project Code CV-2012-2013) 
were analysed by using the validated method. All plasma samples considered in this thesis 
were collected in EDTA tubes and stored in -80˚C prior to use. Patient written consent 
and Ethical approval from Research Ethics Committee were obtained prior to the study. 
 
 
 
 
38 
 
3.3 Analytes extraction and optimisation 
Blank plasma sample (approx. 15mL) from an anonymous donor was used for the analysis 
carried out during the development of the extraction method. From the plasma samples 5mL 
was spiked with 500µg/mL of the analytes (5-HT and 5-HIAA) and kept at -80˚C until further 
experiments. 
3.3.1 Selection of extraction solvents 
Based on literature search, protein precipitation was proposed as the most suitable, simple and 
rapid method to be employed in the extraction of the analytes for a selective LC-MS/MS 
method analysis. During the development of the extraction protocols, the first step was the 
selection of suitable solvent (s) composition to extract 5-HT and 5-HIAA from the plasma 
samples. The choice of solvents to be evaluated was based on published articles using protein 
precipitation techniques. The commonly applied solvents are acetonitrile (ACN), methanol, 
water formic acid and their mixtures. A pseudo 3-dimensional chart showing several 
extraction trials is shown in Fig. 11. 
 
Figure11. A chart of the solvent composition trials. 
(MEOH=methanol, ACN=acetonitrile, ETOH=ethanol, Formic=Formic acid) 
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The preliminary experiments for selection of extraction solvents were carried out using blank 
plasma samples spiked with equal amounts of 5-HT and 5-HIAA (10µg/mL). The general 
procedures applied involves: test tubes containing 100µL plasma samples were treated with 
extracting solvents as shown in Fig. 11. At each step of the solvent addition, the test tubes 
were vortex mixed for approximately 30s then centrifuged for 5 min at 3500 rpm. The 
resultant supernatants were visually evaluated for their clarity. From the test tubes that 
provide clear supernatants, extracts were taken and submitted to LC-MS/MS, the resulting 
signals and clear separation of the monitored peaks were visually assessed.  The remaining 
solutions were kept over-night to check if there would be further precipitation.  
Furthermore, based on the obtained results the extraction solvent system yielding clear 
supernatant, well resolved peaks was selected as the optimal system for extracting 5-HT and 
5-HIAA from human plasma. 
3.4 Mobile phase selection and optimisation of the gradient system 
The selection of the mobile phase was based on previous articles that employed gradient 
mode in the study of biogenic and monoamines. Acetonitrile, formic acid, water and methanol 
are the frequently most applied solvents in the study of such compounds. 
Varying compositions of these solvents and/or their mixtures were tried randomly during the 
selection of the mobile phase gradient condition. Some of the solvent programs tried during 
the optimisation process are shown in Fig 12 (A-J). The chromatograms of the different 
conditions will be shown in section 4.2. 
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(B=water, 0.1%formic acid, C=acetonitrile, 0.1% formic acid, D=methanol, 0.1% formic acid) 
FR=0.2mL/min, CT=20˚C.(CT=column temperature, FR=flow rate). 
 
 
(B=water, 0.1%formic acid, C=acetonitrile, 0.1% formic acid, D=methanol, 0.1% formic acid) 
FR=0.2mL/min, CT=20˚C. 
 
 
 
A 
B 
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(B=water, 0.1%formic acid, C=acetonitrile, 0.1% formic acid) 
FR=0.2mL/min, CT=20˚C. 
 
 
 
 
(B=water, 0.1%formic acid, C=acetonitrile, 0.1% formic acid, D=ethanol) 
FR=0.5mL/min, CT=20˚C. 
 
 
 
C 
D 
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(B=water, 0.1%formic acid, C=acetonitrile, 0.1% formic acid, D=ethanol) 
FR=0.2mL/min, CT=20˚C.  
 
 
 
(B=water, 0.1%formic acid, C=acetonitrile, 0.1% formic acid, D=ethanol) 
FR=0.2mL/min, CT=20˚C. 
 
 
 
F 
E 
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(B=water, 0.1%formic acid, C=acetonitrile, 0.1% formic acid, D=ethanol) 
FR=0.2mL/min, CT=20˚C. 
 
 
 
 
(B=water, 0.1%formic acid, C=acetonitrile, 0.1% formic acid, D=ethanol) 
FR=0.2mL/min, CT=20˚C. 
 
 
 
 
 
G 
H 
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(B=water, 0.1%formic acid, C=acetonitrile, 0.1% formic acid, D=ethanol) 
FR=0.5mL/min, CT=20˚C. 
 
 
 
(B=water, 0.1%formic acid, C=acetonitrile, 0.1% formic acid, D=ethanol) 
FR=0.2mL/min, CT=20˚C. 
 
Figure 12 (A-J). Trials during the selection of gradient condition and other instrumental parameters. 
 
During the course of developing the best gradient program and other instrumental 
optimisation parameters (flow rate and column temperature), injection volumes were studied 
from 30, 25, 20, 10, 5 and 3µL.  
I 
J 
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3.5 Optimising the addition of internal standard 
 
During the course of developing the protocol for adding the internal standards to the blank 
plasma, two procedures of addition were studied. The first involves adding directly the 
solution of internal standard in ACN to the blank plasma samples and the second procedure 
involves drying completely the solvent (ACN) in the stream of Nitrogen before adding the 
blank plasma. The solutions of the two procedures were injected into the LC-MS/MS and the 
signals were obtained and compared. The chromatograms of the two prcedures will be shown 
in section 4.3. 
3.5 Application of Doehlert design to select optimal amounts of internal 
standards. 
 
In this work Doehlert uniform shell design was used to optimise the response factor in order 
to select an optimal amount of internal standard to be used in the method. An initial blank 
plasma sample containing 5-HT and 5-HIAA (100 µg/mL of each analyte) was diluted with 
blank plasma to 1.00, 13.25, 25.50, 37.70, and 50.00 µg/mL Furthermore, a stock of 
100µg/mL of the internal standards (5-CH3o-HT and d2-5-HIAA) in acetonitrile was diluted 
with pure ACN to 4.30, 25.50, and 46.70 µg/mL for optimising the response factor applying 
Doehlert uniform design. The approriate extraction protocol was carried out and the resultant 
supernatants were submitted to LC-MS/MS analysis. 
The response factor (RF) behaviour was studied and modelled using a Doehlert uniform shell 
design in which the concentrations of the analytes (5-HT and 5-HIAA) with their respective 
internal standards (5-CH3o-HT and d2-5-HIAA) were varied simultaneously (Table 2). In the 
design in question (Fig. 13), LC-MS/MS analysis data from the samples of seven 
experimental points in triplicates were used to develop models using regression analysis.  
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Table 2. Concentration of serotonin and 5-hydroxyindole-acetic acid and their respective internal 
standards in the plasma at each experimental point in the two-factor Doehlert design 
Exp. no. Coded 
levels x1 
Coded 
levels x2 
Natural 
levels 
(5-HT) 
Corresponding IS 
(5-CH3o-HT) 
Natural levels 
(5-HIAA) 
Corresponding IS 
(d2-5-HIAA) 
1 -1.00 0.000 1.00 25.5 1.00 25.5 
2 -0.50 0.866 13.25 46.70 13.25 46.70 
3 1.00 0.866 37.75 46.70 37.75 46.70 
4 0.00 0.000 25.50 25.50 25.50 25.50 
5 -0.50 -0.866 13.25 4.30 13.25 4.30 
6 1.00 -0.866 37.75 4.30 37.75 4.30 
7 0.50 0.000 50.00 25.50 50.00 25.50 
 
 
 
 
 
 
 
 
 
Figure 13. Two-factor Doehlert design showing the coded and natural levels of the analytes and 
internal standard at each experimental point. 
 
At each experimental point in the design the obtained peak area signal ratio of analyte and the 
internal standard was used to determine the response factor (RF) according to the expression 
in (Eq. 1). The RF was modelled based on the second order polynomial model (Eq. 3).  
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The adequacy of the developed models from the obtained data was evaluated by statistical 
approach that describes the variation of the obtained values to that of the predicted model; 
where by the variances of the lack-of-fit and pure error are estimated by dividing their 
summation with respective degrees of freedom. The variance ratio of the lack-of-fit error to 
that of pure error known as experimental F-value (Fexp) is used to conclude if the model fits 
the data by comparing with the theoretical F-value (Ftheo). If the Fexp is lower than the Ftheo 
(obtained from F-distribution table) it therefore means that the model is fitted. The procedure 
(Eq. 16-20) employed for calculating the Fexp involves: calculation of the experimental RF 
          according to (Eq. 1) and the average    ̅̅ ̅̅ ̅   of each replicates were obtained. From 
the regression model, calculated RF          was obtained and the sum of residual error (   ), 
pure error (   ) and lack of fit (    ) were calculated according to the following equations: 
                   
                                                Eq. (16) 
              ̅̅̅̅  
                                                     Eq. (17) 
                ̅̅̅̅  
                                                    Eq. (18) 
 
∑         ̅̅ ̅̅          
∑         ̅̅ ̅̅          
                                                        Eq. (19) 
       
      
                                                                            Eq. (20) 
where VPE is the variance of pure error, VRE  is variance of residual error, VLOF  is variance of 
lack-of-fit, K is the number of regression coefficients, N is the number of experiments, P is 
the number of the experimental points, and DF is the degree of freedom. 
In the present work, the F-values were obtained at 97.5% confidence level. 
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3.6 Plasma sample protocol 
The plasma was thawed at room temperature. 100 µL of plasma containing the analytes was 
added to eppendorf tubes, and 100 µL of acetonitrile (ACN) solution containing the internal 
standards (20 µg/mL) was added to the eppendorf tubes containing the plasma. The solution 
was vortex-mixed (Banderlin RK 100 ultra-mixer, Berlin Germany) for approximately 30s 
and centrifuged (Eppendorf AG centrifuge, Hamburg, Germany) at 3500 rpm for 5 min.  The 
supernatants were collected and 100 µL of pure ACN was added to each collected 
supernatant. To completely precipitate the proteins and prepare the samples for LC-MS/MS 
analysis, the supernatants were again vortex-mixed and centrifuged at 3500 rpm for 5min.  
A simplified and concise flow chart of the sample preparation protocol is shown in Fig. 14. 
 
Figure 14. Flow chart of sample preparation protocol. 
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3.7 Method validation 
The selectivity of the method was evaluated by spiking a blank sample with the analytes and 
the internal standards (5-HT, 5-HIAA, and 5-CH3o-HT, d2-5-HIAA). The extracted ion 
chromatograms (177→160,129 m/z for 5-HT, 192→157,146 m/z for 5-HIAA, and 
191→174,143 m/z for 5-CH3o-HT, 194→175 m/z for   -5HIAA) of the spiked samples were 
compared to the ones from the blank samples. The calibration experiment was performed 
using blank plasma samples spiked with 5-HT and 5-HIAA in the concentration range of 0.5-
50 µg/mL. Six concentration levels (0.5, 1.0, 13.25, 25.5, 37.7 and 50 µg/mL) in triplicates 
were prepared according to the protocol previously described in section 3.6 using 20 µg/mL 
of 5-CH3o-HT and d2-5-HIAA internal standards. A linear regression analysis was performed 
for both 5-HT and 5-HIAA. The results will be presented in section 4.5. The LOD (3×SDblank) 
and LOQ (6×SDblank) were estimated visually by using sequential dilution of the spiked 
analytes in plasma. The recovery was determined by comparison of the nominal (spiked blank 
samples) and the calculated concentrations based on the constructed calibration curve models. 
The precision was determined based on repeatability and this was evaluated by determining 
the relative standard deviation (RSD) values of the signal ratio of the analyte to that of the 
internal standard data for the calibration curves. 
3.8 Liquid chromatography ion trap mass spectrometry 
An Agilent 110 series LC/MSD trap, SL model with an electrospray interface (ESI), a 
quaternary pump, degasser, autosampler, thermostatic column compartment, and a variable 
wavelength UV detector was used. The injection volume was 10µL. The column, a Zorbax 
Eclipse-C8 RP 150mm × 4.6mm, 5µm (Agilent Technologies, Palo Alto, CA, USA) was a 
double endcapped column 100% water compatible, which could be operated at a pH range of 
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2-9. It provided improved basic peaks of amines such as serotonin, because of the polar 
groups embedded in the stationary phase and fast conditioning column.  
The column temperature was kept at 20°C and the solvent in gradient mode consisted of water 
with 0.1% formic acid (v/v) (B), acetonitrile with 0.1% formic acid (v/v) (C) and ethanol (D). 
The flow rate was maintained at 0.2mL/min and the UV detector at 254nm. 
The initial condition 80% of B, 20% of D was maintained from 0-5 min and then changed to 
17% of B, 65% of C and 18% of D in 10 min, returned to 80% of B, 20% of D in 2 min held 
for 23 min. The total analysis time was 40 min.  
Using this gradient condition, reproducible retention times were obtained and peak areas were 
monitored from sample to sample. Nitrogen was used as nebulizing (50 psi) and drying gas 
(8L/min) at 350°C. The ESI source was operated in positive mode and ion optics responsible 
for getting the ions in the ion trap such as capillary exit, skimmer, lens and octapoles voltage 
were controlled by using the smart view option with a resolution of 13000 m/z/s (Full width at 
half maximum, FWHM/m/z = 0.6-0.7). A complete system control, data acquisition and 
processing were done using the Chem Station for LC/MSD version from Agilent. The 
transitions were monitored at, m/z 177→160,129 for serotonin, m/z 192→157,146 for 5-
hydroxyindole-acetic acid, and m/z 191→174,143 for 5-CH3o-HT, m/z 194→175 for   -
5HIAA internal standards respectively. The magnitude of the signals was recorded in ion 
counts per seconds (icps).  
3.9 Statistics  
The response factors for the analytes (5-HT and 5-HIAA) are expressed as mean values and 
the standard deviation. The models were generated and simplified using linear regression 
analysis in Microsoft Excel 2010. The statistical adequacy of the models was established by 
an F-test at a 97.5% confidence level as previously mentioned. 
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4. RESULT AND DISCUSSIONS 
4.1 Selection of optimal extraction solvent 
Different extraction protocols were evaluated using several solvents, such as methanol, formic 
acid, acetonitrile (ACN) and water as previously discussed in section 3.3.1. Following several 
trials acetonitrile proved to be the most effective extraction solvent, since it leaves the plasma 
sample free of more protein precipitates unlike other solvents (methanol, formic acid and 
water) or their mixtures that leaves the extract cloudy and thus unsuitable to be injected into 
the LC-MS/MS. The volume of ACN to be used was as well optimised, 1:1, 1:2, 1:3 and 1:4 
of plasma to ACN respectively were evaluated. It was found that; 1:1 leaves the supernatant 
cloudy after long standing hours. The supernatant were only clear for up to 8 hours post 
deproteinisation after which it started to form more precipitates, therefore making it 
unsuitable to be submitted to the LC-MS/MS after long hours. The plasma with high volume 
of ACN was concentrated in vacuum drier (stream of nitrogen was also tried) and re-dissolved 
in ACN during the development of the extraction protocols. During this process, 1:2 of 
plasma to ACN was selected as the most suitable ratio for the precipitation process. Using this 
ratio the supernatant were clear when kept overnight. This is good because the method can be 
successfully applied in routine analysis where numerous samples are often analysed and some 
samples are bound to be kept for long hours after preparation. 
4.2 Selection of the optimal gradient system 
During the course of optimising the gradient program several gradient system, flow rates and 
injection volumes were studied (section 3.4). The chromatograms of the conditions studied 
are shown in Fig. 15. Generally, as can be seen in Fig. 15, some of the gradient conditions 
presented no clear signal, poor separation and/or some background noise. The best gradient 
condition (Table 3) was used with a flow rate of 0.2mL/min, and reproducible retention times 
and well resolved peaks were obtained (Fig. 16). 
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Furthermore, it was found that larger volume of injection (30, 25, 20µL) resulted to poor peak 
separation and poor resolution (Fig. 17). 10µL was found to be the best injection volume, 
giving well separated and well resolved peaks. 
 
 
 
Figure 15. The chromatograms of the different gradient conditions 
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Figure 16. The chromatogram of the best gradient condition showing reproducible retention times of 
the analytes. 
 
Figure 17. The chromatogram of large injection volume. 
 
Table 3. Gradients programme of the mobile phase (eluent). 
TIME 
(min) 
B% 
(H20, 0.1% HCOOH) 
C% 
(ACN, 0.1% HCOOH) 
D% 
(ETHANOL) 
0 80 0 20 
5 80 0 20 
15 17 65 18 
17 80 0 20 
40 80 0 20 
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4.3 Procedure for addition of internal standard 
Two procedures were studied during the course of developing the protocol for adding the 
internal standards to the blank samples. The results showed that there was no clear difference 
in the obtained signals from the two procedures (Fig. 18). Therefore, since the present method 
also aims at developing a simple, less time consuming protocol, the procedure that involves 
adding the internal standard in ACN solution into the plasma without drying was preferred as 
the procedure of choice for the developed method. 
 
 
Figure 18. Overlap chromatogram of the two procedures for adding internal standard using two 
different concentrations (A=25µg/mL, B=30 µg/mL). 
 
4.3.1 Optimisation of the internal standard 
 
A protocol for simultaneous analyses of serotonin and 5-hydroxyindole acetic acid has been 
developed. The behaviour of the analyte and internal standard has been studied and modelled 
using Doehlert uniform shell design (section 3.5) to select the optimal amount of both internal 
standards. Furthermore, the selection of the optimal internal standard was based on 
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mathematical models using regression analysis and visualizing the concentration in the 
response surface plot of the obtained model to find a region where the response factor remain 
relatively constant over the studied analytical concentration range. 
The seven experimental point solutions of plasma prepared in triplicates containing different 
concentration of 5-HT, 5-HIAA and their corresponding internal standards (Table 2) were 
injected randomly into the chromatographic system and detected by the ion trap tandem MS. 
The computed response factors at the seven experimental points are presented in Table 4. 
Table 4. Summary of RFs for the analytes (5-HT and 5-HIAA) at each experimental points expressed 
as mean±standard deviation 
Exp. No Analytes conc. 
(µg/mL) 
IS conc. (µg/mL) RFs for 5-HT RFs for 5-HIAA 
1 1 25.5 1.8±0.13 2.63±0.26 
2 13.25 46.70 2.81±0.02 11.90±1.05 
3 37.75 46.70 4.07±0.11 15.22±1.66 
4 25.50 25.50 4.31±0.13 18.56±0.72 
5 13.75 4.30 5.52±0.22 39.71±16.65 
6 37.75 4.30 7.63±0.26 34.91±7.28 
7 50.00 25.50 5.87±0.16 21.56±5.48 
 
The transitions were monitored at, 177→160,129 m/z for serotonin, 192→157,146 m/z for 5-
hydroxyindole-3-acetic acid, and 177→174,143 m/z for 5-CH3o-HT, 194→175 m/z for   -
5HIAA internal standards respectively. The magnitude of the signals was recorded in ion 
counts per seconds (icps).  
The analyses time for the solution was 40 min and the elution times were approximately 9.2, 
13.4 for 5-HT, 5-CH3o-HT and 16.0, 13.6 for 5-HIAA, d2-5-HIAA respectively. The 
extracted ion chromatograms (EICs) were extracted, integrated and the RFs calculated using 
(Eq. 1).  
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4.4 Modelling the RF as a function of 5-HT and 5-HIAA and their internal standards 
(5-CH3o-HT and d2-5-HIAA respectively). 
 
Various polynomial models were evaluated for the system 5-HT, 5-HIAA and their internal 
standards (5-CH3o-HT, d2-5-HIAA respectively) and it was found that full second order 
polynomial model with six coefficients (Eq. 3) was adequate to describe the behaviour of 
serotonin and 5-hydroxyindole-acetic acid and their corresponding internal standards. The 
adequacy of the model was established by comparing the experimental lack of fit to pure error 
variance ratio (Fexp = 3.57 for 5-HIAA, Fexp = 6.24 for 5-HT ) with the theoretical (Ftheo = 6.42 
for 5-HIAA, 6.93 for 5-HT at 97.5% confidence levels) values at determined degrees of 
freedom (Eq. 20). The compared variances gives enough evidence to support the adequacy of 
Eq. 21 and 22 to predict the RF over the experimental domain in the study.  
During the modelling, models with lesser number of coefficients were also considered (Eq. 2), 
but it was found that this type of model with lower number of terms was not statistically 
adequate for modelling the behaviour of the RF as a function of the analytical concentrations. 
The models did not fulfil the condition stated in section 3.5 (that if the Fexp is lower than the 
Ftheo it means that the model is fitted). 
The result of the RFs are presented as mean values in the surface plot (Fig. 19) generated 
from the obtained model. The models are shown below (Eq. 21 and 22).  
                                                   
          
                    
                                
  
                                                                                                 
 
                                                     
        
                    
                              
  
Eq. (22) 
Eq. (21) 
57 
 
 The response surface plots are shown in (Fig. 19A and B).  
 
 
 
Figure 19.  A. Modelling of the response factor as a function 5-HIAA and d2-5-HIAA, B. Modelling of 
the response factor as a function 5-HT and 5-CH3o-HT 
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The RF values 5.8±4.1, 17.7±4.1, 25.1±4.9, 37.7±4.4 were estimated in the ranges of 25-50 
µg/mL, 21-24 µg/mL, 8-25 µg/mL 0-7 µg/mL respectively for d2-5-HIAA (Fig. 19A) and 
1.8±0.9, 3.4±1.1, 3.6±1.1, 5.1±1.4, 8.2±0.5 were estimated in the ranges of 25-50 µg/mL, 8-
50 µg/mL, 23-50 µg/mL, 9-22 µg/mL, 0-8 µg/mL respectively  for 5-CH3o-HT (Fig. 19B). 
Every region in the surface plot encompasses concentration regions for both analytical species 
where it is expected to find constant RF. Furthermore, it is shown that the system described 
by the analytes (5-HT and 5-HIAA) and their internal standards (5-CH3o-HT and d2-5-HIAA) 
in Fig. 19A and B exhibits an inverse relationship. This means that as the concentration of the 
internal standards increases the mean value of the RF decreases proportionally and vice versa 
(Fig. 19A and B). This trend suggests a decreasing sensitivity of the analyses as the 
concentration of internal standard increases. Consequently, a critical look at the response 
surface plots in Fig. 19A and B for a region where the surface plot remains relatively constant 
to select optimal concentration of internal standards to be spiked in the plasma samples. The 
optimal concencentrations of 5-CH3o-HT and d2-5-HIAA to be used in analysis of 5-HT and 
5-HIAA can be from 9-22 µg/mL for 5-CH3o-HT and 8-25 µg/mL for d2-5-HIAA according 
to (Fig. 19A and B). As a result 20 µg/mL was considered as the optimal amount of internal 
standard for the quantification of 5-HT and 5-HIAA in the plasma samples.  At this 
concentration of d2-5-HIAA the RF values remains relatively constant over the entire 
analytical range while for 5-CH3o-HT the RF values was not however constant over the entire 
analytical range but  this concentration was satisfactory to be considered as the most adequate 
concentration for the developed method. The average RF values at this region is 3.6±1.1 for 
5-CH3o-HT and 25.1±4.9 for d2-5-HIAA. 
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Extracted ion chromatograms of 5-HT, 5-HIAA, 5-CH3o-HT and d2-5-HIAA  and their 
corresponding mass spectra are shown in Fig. 20-23. 
 
 
Figure 20. Chromatogram of 5-HT (A) and its mass spectrum (B). 
 
 
60 
 
 
Figure 21. Chromatogram of 5-CH3o-HT (A) and its mass spectrum (B). 
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Figure 22. Chromatogram of 5-HIAA (A) and its mass spectrum (B). 
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Figure 23. Chromatogram of d
2
5-HIAA (A) and its mass spectrum (B). 
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Figure 24. A. Overlay chromatogram of 5-HT and its internal standard, showing their fragment 
masses. B. Overlay chromatogram of 5-HIAA and its internal standard, showing their fragment 
masses. 
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4.5 Validation and analytical assessment 
Plasma calibration samples containing a mixture of 5-HT and 5-HIAA in the range of 0-
50µg/mL were spiked with fixed and optimal amount of the corresponding internal standards 
(20µg/mL of 5-CH3o-HT and d2-5-HIAA respectively) selected from the result of the 
response factor behaviour. The analytical performance parameters such as; range, linearity, 
selectivity, recovery, precision, limit of detection and limit of quantification were determined. 
The method was linear over the studied range of concentration. The correlation coefficients 
was r
2 
= 0.9823 for serotonin and r
2 
= 0.9892 for 5-hydroxyindole-acetic acid which indicates 
strong correlation between the studied concentration of the analytes and the signal. However 
the response of the metabolite, 5-HIAA was not linear when the solution was analysed after 
some hours of standing. This could be attributed to degradation. The linear regression graph 
of the two species are shown in Fig. 25A and B.  
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Figure 25. A. Linear regression graph of the signal of the ratio 5-HIAA and d2-5HIAA against the 
concentrations.B. Linear regression graph of the signal of the ratio 5-HT and 5-CH3o-HT     against the 
concentrations. 
The selectivity of the method was determined by the EIC of a sample spiked with 5-HT and 5-
HIAA to the EIC from a blank plasma samples. The method was very selective towards the 
two analytical species as seen in the overlay chromatogram (Fig. 24A and B). The precision 
of the method for 5-HT and 5-HIAA was achieved based on repeatability with RSD of 3.07-
7.73% and 3.93-9.99% respectively. The percentage recoveries were 83-119% and 84-116% 
for serotonin and 5-HIAA respectively, which shows good accuracy of the developed method. 
The limit of detection and limit of quanitification for both analytes were determined to be 0.5 
µg/mL and 1 µg/mL respectively suggesting good sensitivity of the method. Furthermore, in 
comparison of the present study to previous research. Several analytical methods [70-165] 
have been employed in the study of serotonin in plasma. LC-MS/MS has been used; 4.6 
nmol/L was reported by De Jong et al. [53], 18.2 nmol/L by Moriarty et el. [52], 1.5 nmol/L 
by Monaghan et al. [60]. HPLC with different detections have been employed as well and 
varying concentrations have been reported, 114 nmol/L [72], 44 nmol/L [83], 141 nmol/L 
[108] etc. Radioenzymatic assay has also been employed and different concentrations such as 
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38 nmol/L [78], 22.6 nmol/L [82], 2 nmol/L [100], and 0.6 nmol/L [122] have been reported. 
As seen in Table 1, mass spectrometric [53, 115] and radioenzymatic methods reported lower 
estimate of serotonin in plasma compared to HPLC methods. The present study has reported 
LOD of 0.5µg/mL (0.003 nmol/L) and LOQ of 1 µg/mL (0.006 nmol/L) which has given it 
superiority over the previous methods. A random search using key words such as “normal 
plasma levels of serotonin” and “plasma concentration of serotonin” revealed varying and 
conflicting values. However, majority of the search results seems to be within the range of 
0.4-5 µg/mL (0.002-0.030 nmol/L). Also the levels of serotonin and its associated metabolite 
is age dependent thus the reported values accounts for normal adult, since the level is 
increased in children and younger age groups [8]. Therefore, supposing that the above range 
is correct, it can be said that some of the previous methods reported values that may give false 
positives. 
4.6 Method application on plasma samples from a research study 
Ten human plasma samples from a project related to the determination of serotonin and 
associated metabolites in plasma from pathological patients subjected to a diet rich in 
vegetables were examined by using the developed method under optimal conditions.  
The quantitative analyses (Table 5) revealed that in the majority of the samples the serotonin 
levels were lower than the 5-hydroxyindole-acetic acid levels.  
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Table 5. Plasma concentration of serotonin and its acid metabolite in plasma samples from 10 
vegetarian patients. 
No 5-HT (µg/ml) 5-HIAA (µg/ml) 
1 10.21±1.08 16.03±1.48 
2 Below LOD 2.36±0.27 
3 13.26±1.17 16.31±1.03 
4 8.60±0.57 11.35±0.96 
5 11.60±1.10 13.46±1.23 
6 Below LOD Below LOQ 
7 11.99±0.56 15.35±0.87 
8 Below LOD below LOQ 
9 7.69±0.72 9.30±0.69 
10 12.60±1.36 15.75±1.47 
 
The results are expressed as mean±standard deviation of triplicate values; LOD means limit of 
detection (0.5 µg/mL), and LOQ means limit of quanitification (1 µg/mL). 
 
This observation supports the earlier report [18], that intake of foods which are rich in 
tryptophan (precursor of serotonin) increases the synthesis of serotonin. Thus, there will be 
surplus serotonin in circulation, which will result to proportional increase in plasma levels of 
5-HIAA since more serotonin will be available for degradation by the liver to 5-HIAA. Also 
when the serotonergic activity is high, more serotonin is released in the synapses, and 
consequently, metabolized to 5-HIAA. Biochemically, in certain health conditions such as 
carcinoid tumour, the carcinoid causes abnormal of tryptophan metabolism, in which as much 
as 60 %, other than the normal 1 %, of tryptophan may follow the serotonergic pathway [13]. 
Moreover, elevated plasma serotonin levels are hazardous, rapid elimination mechanisms 
evolve to clear the excess 5-HT thereby converting it to its acid metabolite.  
4.7 Concluding remarks 
5-hydroxyindole-acetic acid has been utilised as a biomarker for carcinoid tumours and other 
pathological diseases and serotonin has been used as an index for assessment of 
gastrointestinal disorders (such as irretable bowel syndrome) as well as emotional related 
complications (including depression). We have developed a method that proposes a simple 
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and rapid protocol for the simultaneous extraction and subsequent determination of serotonin 
and 5-hydroxyindole-acetic acid in human plasma by liquid chromatogaphy tandem mass 
spectrometry. The extraction protocols and other sample preparation steps are quite simple 
and do not require much downstream preparation protocols. Nonethless, there were dificulties 
encountered during the method development process most notably in the development of the 
extraction protocols. Such set backs includes the clogging of the LC-MS/MS by protein 
precipitates, however, the set back was subsquently circumvented by reevaluating the sample 
preparation procedures. 
The method may be suitable to be applied as a biomarker for determination of 5-HT and 5-
HIAA in plasma in patients suffering from several neuronal and pathological diseases such as 
carcinoid tumour (in which elevated levels of these compunds may occur) and depression 
related complications where both compounds are implicated and thus may be adequate to be 
applied in routine analysis of 5-HT and 5-HIAA. The physiological concentration of 5-HT in 
plasma is several times lower than compared to whole blood concentration, thus making the 
measurement of serotonin in plasma very demanding and require a very sensitive technique as 
the method reported here. The developd method proved to be quite sensitive, selective and 
relatively no background noise in the chromatogram as shown in Fig. 24A and B.  
In addition, to the best of our knowledge this is the first reported method that used a Doehlert 
design to optimize multiple amounts of internal standard for the simultaneous determination 
of serotonin and 5-hydroxyindole-acetic acid in plasma samples. This approach is 
advantageous in that it helps to simulate different concentrations of internal standards across 
several concentrations of the analytes as if it were in real terms thus avoiding the preparation 
of several solutions. The developed method has reproducible retention times with acceptable 
variations of less than 0.5% between samples. 
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